Walker Robert Edward 4

What Happened

• Walker Robert Edward, Executive Vice President, R&D at Novavax (NVAX), received two equity awards on April 14, 2026: a stock option covering 99,500 shares and 66,000 restricted stock units (RSUs). Both awards are recorded at $0.00 (awarded, not purchased), so there was no cash paid by Walker.
• The option and RSU grants are derivative awards (not open‑market buys or sells) and will vest over time according to the company plan terms.

Key Details

• Transaction date: April 14, 2026; Form 4 filed April 16, 2026 (within the typical 2-business-day reporting window).
• Reported price: $0.00 for both grants (A = award/grant).
• Option grant: 99,500 shares. Vesting: 25% vests on first anniversary, remaining 75% vests in equal monthly installments over the following three years (see footnote F1).
• RSU grant: 66,000 RSUs. Each RSU converts to one share if vested; RSUs vest one‑third on each of the first three anniversaries of the grant (see footnotes F2 and F3).
• Shares owned after the transaction: not specified in the details you provided in this filing.
• No immediate sale or cashless exercise reported—these are time‑based awards subject to continued employment.

Context

• Options give the holder the right to buy company stock at a set price (vesting schedule must be met first); RSUs are promises to deliver shares once vesting conditions are satisfied. These awards are common as compensation and do not by themselves indicate buying or selling sentiment.